The company has been pushing for more reimbursement of its three marketed DTx products in the US following a first FDA approval in 2017.
Pear said that the Ohio Department of Mental Health and Addiction Services (OhioMHAS) and RecoveryOhio are providing access to Pear’s FDA-approved DTx reSET and reSET‑O, for treatment of substance use disorder and opioid use disorders, respectively.
Funding is provided by the State Opioid Response (SOR) 2.0 grant, administered by OhioMHAS, and part of the US Department of Health and Human Services’ Substance Abuse and Mental Health Services Administration (SAMHSA) SOR grant programme for people in need of prevention, treatment and recovery support for opioid use disorder.
Pear Announces Ohio Department of Mental Health and Addiction Services will Provide Access to Prescription Digital Therapeutics to Help Local Communities Continue Fight Against Opioid Addiction (press release):
Pear Therapeutics, Inc. announced today that the Ohio Department of Mental Health and Addiction Services (OhioMHAS) and RecoveryOhio are providing access to Pear’s FDA-authorized prescription digital therapeutics (PDTs) reSET® and reSET‑O® for the treatment of substance use disorder (SUD) and opioid use disorder (OUD), respectively. Eligible patients will be prescribed and treated with reSET or reSET‑O to help communities throughout Ohio continue the fight against addiction … Pear was awarded a grant to provide reSET and reSET‑O under the ‘Use of Innovation’ program that supports technology and innovation advancements in Ohio’s behavioral health care delivery system to support Ohioans on their recovery journeys. Ohio marks the third SOR grant awarded to Pear in 2021, with other SOR grants awarded by Indiana and Kentucky.…
“While the pandemic has rightfully been front and center in everyone’s minds, the opioid epidemic hasn’t gone away – it persists as a threat to our citizens and our communities,” said OhioMHAS Director Lori Criss. “This funding will help partners like Pear Therapeutics connect even more Ohioans to treatment and recovery services and support their use of new technology and innovation to stem the tide of addiction.”
reSET and reSET‑O have been tested in real-world use and randomized controlled trials, with results published in peer-reviewed medical journals. Both products, which are adjunctive to outpatient counselling, provide patients with algorithm-driven cognitive behavioral therapy, fluency training, and contingency management, while clinicians receive access to clinical dashboards to inform in-office and tele visits. reSET is used as a monotherapy for patients 18 years of age or older with substance use disorder and reSET‑O is used in combination with transmucosal buprenorphine for patients 18 years of age or older with opioid use disorder.